Brokers Set Expectations for Insmed FY2026 Earnings

Insmed Incorporated (NASDAQ:INSM - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Insmed in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutical company will post earnings per share of ($4.24) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Insmed's current full-year earnings is ($4.56) per share.

INSM has been the subject of a number of other reports. Stifel Nicolaus decreased their price objective on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. UBS Group decreased their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Monday, May 12th. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $98.93.

Insmed Stock Up 28.7%

Shares of INSM stock traded up $20.25 on Tuesday, reaching $90.93. 15,641,664 shares of the company's stock traded hands, compared to its average volume of 2,127,184. The company has a market capitalization of $16.56 billion, a P/E ratio of -16.27 and a beta of 0.80. Insmed has a 12-month low of $56.03 and a 12-month high of $95.94. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business's 50 day moving average price is $69.23 and its two-hundred day moving average price is $73.01.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same quarter last year, the company posted ($1.06) EPS. The firm's revenue was up 22.9% compared to the same quarter last year.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently made changes to their positions in the company. Darwin Global Management Ltd. grew its holdings in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Norges Bank acquired a new position in Insmed during the 4th quarter worth about $126,606,000. Adage Capital Partners GP L.L.C. lifted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after buying an additional 1,799,382 shares in the last quarter. Nuveen LLC bought a new position in Insmed in the 1st quarter worth approximately $88,351,000. Finally, Vanguard Group Inc. increased its stake in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after buying an additional 1,075,796 shares during the period.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 21,057 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $67.65, for a total transaction of $1,424,506.05. Following the completion of the transaction, the chief executive officer now owns 314,230 shares in the company, valued at $21,257,659.50. This trade represents a 6.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Clarissa Desjardins purchased 1,895 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was bought at an average cost of $66.87 per share, for a total transaction of $126,718.65. Following the purchase, the director now owns 1,895 shares in the company, valued at $126,718.65. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 162,994 shares of company stock valued at $11,320,938 over the last quarter. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.